About Us
Overview
Our Business
Board of Directors
Executive Leadership Team
Biocon Biologics Malaysia
Scientific Publications
Awards & Recognition
Our Legacy
Products
Overview
Product Locator
Business
Overview
Global Biosimilars Portfolio
Oncology
Immunology
Diabetology
Ophthalmology
Bone Health & Others
Global Footprint
Partners
Branded Formulations India
Metabolics
Oncology
Immunotherapy
Nephrology
CCD
COVID-19 Care Portfolio
Capabilities
Research & Development
Quality & Compliance
Global Scale Manufacturing
Biocon Biologics Malaysia
Commitment
Overview
Investors
Overview
Governance & Policies
News
Overview
Press Releases
Company Statements
Stories
Media Contacts
Careers
Working With Us
Now Hiring
Stories
Contact Us
Brand Stories
Employee Stories
Patient Stories
Press Releases 2020
Biocon Biologics
/
News – Posts
/
Press Releases
/
Press Releases 2020
Biocon Biologics signs an MoU with CSSC in Tanzania for Mission 10 cents
Tue, 15-Dec-2020
Posted by: Biocon Biologics
No Comments
Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs
Sat, 07-Nov-2020
Posted by: Biocon Biologics
No Comments
Biocon Ranked Among Top 5 Biotech Employers Globally
Fri, 30-Oct-2020
Posted by: Biocon Biologics
No Comments
Biocon Q2FY21 Revenue at Rs 1,760 Cr, Up 10%; EBITDA at Rs 407 Cr; Net Profit (before exceptional item & discontinuing operations) at Rs 174 Cr; Generics Up 8% at Rs 599 Cr; Biosimilars Up 11% at Rs 676 Cr; Research Services Up 12% at Rs 520 Cr.
Fri, 23-Oct-2020
Posted by: Biocon Biologics
No Comments
Biocon Foundation Signs MoU with Bangalore Metro to Contribute Towards Building Metro Station in Hebbagodi
Thu, 08-Oct-2020
Posted by: Biocon Biologics
No Comments
Biocon Biologics to Roll Out ‘Mission 10 cents’ in Philippines; Signs MoU with 2 Municipal Governments & reach52 to enable Affordable Access to Quality Insulins
Wed, 30-Sep-2020
Posted by: Biocon Biologics
No Comments
Biocon Biologics and Mylan Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes
Mon, 31-Aug-2020
Posted by: Biocon Biologics
No Comments
Tata Capital Growth Fund to Invest ~USD 30 million (Rs 225 Crore) in Biocon Biologics for an Equity Stake of 0.85% Deal Values Biocon Biologics at USD 3.5 Billion.
Fri, 31-Jul-2020
Posted by: Biocon Biologics
No Comments
Biocon Q1FY21 Revenue at Rs 1,690 Cr, Up 14%; EBITDA at Rs 432 Cr; Net Profit (from continuing ops) at Rs 153 Cr Generics up 16% at Rs 599 Cr, Biosimilars up 19% at Rs 692 Cr
Thu, 23-Jul-2020
Posted by: Biocon Biologics
No Comments
Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins
Tue, 21-Jul-2020
Posted by: Biocon Biologics
No Comments
1
2
3